Core Viewpoint - The original subscription agreement of Guofu Quantum has become invalid due to unmet conditions and the decision to not proceed with the original subscription matters, leading to no claims between the parties involved [1] Group 1: Subscription Agreement Details - The original subscription agreement's deadline was September 4, 2025, and the necessary conditions were not fulfilled [1] - The company has entered into eleven independent subscription agreements with eleven subscribers, agreeing to issue a total of 745,168,534 shares at a subscription price of HKD 1.78 per share [1] - The subscription price represents a discount of approximately 16.43% compared to the closing price of HKD 2.13 on the Hong Kong Stock Exchange on the date of the agreement [1] Group 2: Financial Implications - The total amount raised from the subscription is expected to be approximately HKD 1.326 billion, with a net amount of about HKD 1.32 billion after deducting related costs and expenses [1] - The net subscription price per share is approximately HKD 1.77 based on the aforementioned figures [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 網址：https://290.com.hk （股份代號：290） 原訂根據一般授權認購新股份失效 及 新訂根據一般授權認購新股份 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 本公告不會直接或間接於或向美國（包括美國的領土及屬地、任何州以及哥倫比 亞特區）派發。本公告並不構成或組成在美國境內購買或認購證券的任何要約或 招攬的一部分。本公告所述認購股份並無亦不會根據一九三三年美國證券法（「證 券法」）登記。 認購股份不得在美國境內或向美籍人士（定義見證券法S規例）或以其名義或為其 利益提呈發售或出售，惟獲豁免遵守證券法登記規定者除外。證券將不會於美國 公開發售。 GoFintech Quantum Innovation Limited 國富量子創新有限公司 （前稱 GoFintech Innovation Limited 國富創新有限公司） （於開曼群島註冊成立之有限公司） 由於認 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國富量子創新有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00290 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.1 HKD | | 2,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.1 HKD | | 2,000,000,000 | ...

Group 1 - The company announced the resignation of Ms. Yan Xin as the company secretary effective from September 4, 2025 [1] - Ms. Li Peihua has been appointed as the new company secretary, authorized representative, and legal process agent [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 GoFintech Quantum Innovation Limited 國富量子創新有限公司 李女士持有香港科技大學社會科學專業文學碩士學位。彼為香港公司治理公會及 英國特許公司治理公會會士。李女士在公司秘書、企業管治、投資者關係及企業管 理方面有十餘年經驗。 1 (i) 嚴欣女士（「嚴女士」）已辭任本公司公司秘書（「公司秘書」）之職務，並不再 擔任根據香港聯合交易所有限公司（「聯交所」）證券上市規則第3.05條規定之 本公司其中一名授權代表（「授權代表」）；及公司條例（香港法例第622章）第 16部項下及上市規則第19.05（2）條項下代表本公司於香港接受法律程序文件 及通知之法律程序文件代理人（「法律程序文件代理人」）。 (ii) 李裴華女士（「李女士」）已獲委任為公司秘書，授權代表及法律程序文件代理 人。 董事會謹藉此機會衷心感謝嚴女士於任期內對本公司作出之寶貴貢獻，同時歡迎 李女士就任。 承 ...

Core Viewpoint - Guofu Quantum Innovation Co., Ltd. is strategically positioning itself in the RWA (Real World Asset) market by launching the RWA8 Fund, aiming to enhance its competitiveness in the digital asset space and contribute to Hong Kong's economic digital transformation [1][5]. Group 1: Fund and Market Positioning - The RWA8 Fund is a key component of Guofu Quantum's Pre-RWA strategy, focusing on early investments in tokenizable assets such as equity, income rights, bonds, and art [3]. - The RWA market is projected to exceed trillions of dollars by 2030, attracting intense competition among global financial institutions [3]. - Guofu Quantum holds critical licenses and cross-border business qualifications, enabling it to support the tokenization and circulation of underlying assets effectively [3]. Group 2: Business Model and Ecosystem Development - The establishment of the RWA8 Fund signifies a comprehensive layout of Guofu Quantum's RWA ecosystem, transitioning from a traditional investor to an operational and service provider within the RWA space [4]. - The company aims to diversify its revenue streams from solely investment returns to include management fees, underwriting fees, and transaction fees, enhancing profitability [4]. - Guofu Quantum is building a "five-in-one" ecosystem that integrates exchanges, RWA investment banks, Pre-RWA funds, RWA secondary market funds, and fintech [4]. Group 3: Strategic Ambitions and Impact - The RWA8 Fund is not just a financial vehicle but a strategic initiative to position Hong Kong as a digital transformation hub, aligning with the government's vision for eight key centers [5][6]. - Guofu Quantum's approach is seen as a bridge between traditional assets and the Web3 industry, aiming to create a "super complex" for the RWA ecosystem in Hong Kong [7]. - The company's strategic moves reflect a deep understanding of market trends and a commitment to reshaping the digital economy landscape in Hong Kong [7].

Core Viewpoint - Guofu Quantum Innovation Co., Ltd. is strategically positioning itself in the RWA (Real World Asset) market by launching the RWA8 Fund, aiming to enhance its competitiveness in the RWA and on-chain finance sectors while contributing to Hong Kong's economic digital transformation [1][5][7] Group 1: Fund and Market Positioning - The RWA8 Fund is a key component of Guofu Quantum's Pre-RWA strategic layout, focusing on preemptive investments in tokenizable quality underlying assets such as equity, income rights, bonds, and artworks [3] - The RWA market is projected to exceed trillions of dollars by 2030, attracting intense competition among global financial institutions [3] - Guofu Quantum holds significant licenses and qualifications, enabling it to provide comprehensive support for the tokenization and on-chain circulation of underlying assets, thereby solidifying its competitive position [3] Group 2: Business Model and Ecosystem Development - Guofu Quantum aims to create a comprehensive ecosystem encompassing exchanges, RWA investment banks, Pre-RWA funds, RWA secondary market funds, and fintech, marking a significant enhancement of its RWA value chain [4] - The company is transitioning from a traditional investment entity to an RWA ecosystem operator and service provider, diversifying its revenue streams to include management fees, underwriting fees, and transaction fees [4] Group 3: Strategic Goals and Industry Impact - The establishment of the RWA8 Fund is not merely a fund investment but a strategic move to become a foundational builder of Hong Kong's economic digital transformation [5][6] - Guofu Quantum's strategy aligns with the Hong Kong government's vision of developing eight key centers, aiming to digitize and tokenize assets related to these centers [5] - The company's approach represents a significant shift in traditional finance, positioning it as a bridge between cryptocurrency and the real economy, with the potential to reshape Hong Kong's digital economy landscape [7]

Core Viewpoint - The collaboration between Meinian Health, Guofu Quantum, and Jingbeifang aims to explore the value release of digital assets in the healthcare sector, leveraging each company's strengths to innovate and upgrade the health industry [1][4]. Group 1: Collaboration and Strategic Goals - Meinian Health's subsidiary has signed a framework agreement with Guofu Quantum and Jingbeifang to explore comprehensive business opportunities in the digital asset RWA (Real World Asset) field [1]. - The partnership will focus on the tokenization of medical assets under the regulatory frameworks of mainland China and Hong Kong, aiming to reshape the value chain in the healthcare sector [1][4]. - This collaboration is expected to transform Meinian Health from a "health examination service provider" to a "medical data technology platform," enhancing its cash flow structure and expanding its business capabilities [4]. Group 2: Asset and Data Strengths - As of 2024, Meinian Health operates 576 health examination centers equipped with advanced medical devices, establishing a solid foundation of tangible assets [2]. - The company has served over 200 million people, with more than 25 million health examinations conducted in 2024, accumulating extensive multimodal health data [2][9]. - Meinian Health has developed AI applications for health management, including intelligent health managers and disease risk prediction models, which enhance its service offerings and operational efficiency [2][8]. Group 3: Research and Development Achievements - Meinian Health has led a national key research project to build a health examination big data cloud platform, gathering over 130 million health examination records, which supports the value of its data assets [6][7]. - The company has published numerous research papers based on its health examination data, contributing to significant findings in public health and disease prevention [17][18]. - Collaborations with prestigious medical institutions have resulted in breakthroughs in various health-related research projects, further validating the commercial potential of its data [16][18]. Group 4: Unique Data Advantages - Meinian Health's health examination data focuses on asymptomatic populations, providing unique insights for early disease detection and prevention [11]. - The data's medical-grade accuracy and comprehensive multimodal integration enhance its value for serious medical research compared to consumer-grade health monitoring devices [12][13]. - The company's annual health examinations create a natural cohort tracking mechanism, ensuring high compliance and data integrity for longitudinal studies [14][15].

Group 1 - Hong Kong Stock Exchange criticized Fuhong Hanlin for misusing IPO fundraising, highlighting governance and compliance issues [1] - Fuhong Hanlin's former CEO Liu Shigao was also reprimanded and required to undergo training [1] Group 2 - Xiansheng Pharmaceutical plans to raise approximately HKD 15.54 billion through a placement of 121 million shares at HKD 12.95 each, with about 90% allocated for R&D [2] - The funding will support clinical research for new drugs in China and the US, as well as expanding indications for approved innovative drugs [2] Group 3 - Huajian Medical announced the acquisition of a 20.31% stake in Guofu Quantum for approximately HKD 31.42 billion, making it the largest shareholder [3] - This acquisition is a strategic move to advance Huajian Medical's RWA (Real World Asset) tokenization initiative [3] Group 4 - Lighter Health Group submitted a prospectus for listing on the Hong Kong Stock Exchange, focusing on comprehensive health services and insurance solutions [4] - The company reported significant revenue growth from HKD 394 million in 2022 to HKD 945 million in 2024, but experienced a decline in gross margin from 82.6% to 38.3% [4]

Group 1 - The Hang Seng Index fell by 0.4%, while the Hang Seng Tech Index decreased by 0.54%, with a total turnover of 152 billion HKD in the Hong Kong stock market during the morning session [1] - The Hang Seng Biotechnology Index rose by 1%, with notable gains from companies such as MicroPort Scientific Corporation (02252) up by 10%, and Four Seasons Medicine (00460) up by 8% [1] Group 2 - MicroPort Scientific Corporation (02252) saw a rise of over 10%, indicating renewed interest in the robotics industry and steady progress in the company's commercialization efforts [2] - Dongyang Sunshine Pharmaceutical (06887) increased by nearly 7%, reporting a mid-term gross profit of 1.468 billion HKD, with key data on Ifenprodil presented at the US IPF summit [2] - Chuangsheng Group-B (06628) surged over 28%, with a mid-term net loss narrowing by 17.9%, and TST001 research data making its debut at ASCO [2] - Kingsoft Holdings (03918) rose by over 6%, with first-half performance exceeding market expectations, although uncertainties remain regarding the Naga3 project according to Citigroup [2] - Green Power Environmental (01330) increased by over 7%, with a 24.49% year-on-year increase in net profit attributable to shareholders, driven by its gas supply business [2] - Hylink Technology (01860) rose by 7.9%, with first-half revenue increasing by 40% year-on-year, and institutions optimistic about the continued release of the Mintegral platform's flywheel effect [2] - Zhi Zi Cheng Technology (09911) rose by over 6%, with first-half net profit nearly doubling, and the group's gross profit margin expected to improve significantly year-on-year [2] - Four Seasons Medicine (00460) rose by over 7%, achieving profitability in the first half and making substantial progress in its AI + medical beauty strategic layout [2] - Guofu Quantum (00290) increased by 6.86%, with a cumulative increase of nearly 1.8 times this year, collaborating with Huajian Medical to advance RWA ecosystem construction [2] - New Idea Network Group (01686) fell by over 17% post-results, with annual net profit increasing by 8% to 979 million HKD [2]